Last reviewed · How we verify
D-0120 in combination with Allopurinol
D-0120 in combination with Allopurinol is a Small molecule drug developed by InventisBio Co., Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | D-0120 in combination with Allopurinol |
|---|---|
| Sponsor | InventisBio Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout (PHASE2)
- Evaluation of PK and Safety of D-0120 and Allopurinol (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D-0120 in combination with Allopurinol CI brief — competitive landscape report
- D-0120 in combination with Allopurinol updates RSS · CI watch RSS
- InventisBio Co., Ltd portfolio CI
Frequently asked questions about D-0120 in combination with Allopurinol
What is D-0120 in combination with Allopurinol?
D-0120 in combination with Allopurinol is a Small molecule drug developed by InventisBio Co., Ltd.
Who makes D-0120 in combination with Allopurinol?
D-0120 in combination with Allopurinol is developed by InventisBio Co., Ltd (see full InventisBio Co., Ltd pipeline at /company/inventisbio-co-ltd).
What development phase is D-0120 in combination with Allopurinol in?
D-0120 in combination with Allopurinol is in Phase 1.